1) The study examined the effects of a monoclonal anti-CGRP antibody on stress-induced colonic hypersensitivity in a rat model.
2) The antibody decreased colonic hypersensitivity induced by chronic adult stress or unpredictable early life stress without affecting colonic compliance.
3) The antibody also inhibited stress-induced signaling in the thoracolumbar spinal cord that is associated with persistent visceral pain.
Alphabet Soup - Biomarker testing for colon and rectal cancer patients - KRAS...Fight Colorectal Cancer
Dr. Cathy Eng's presentation regarding biomarkers. Explaining why colon and rectal cancer patients should undergo testing for KRAS, NRAS and other tumor tests.
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2QIAGEN
Advanced prostate cancer is highly heterogeneous but this inter-patient heterogeneity has until recently not been understood. We have through an international research effort dissected the molecular landscape of advanced castration resistant prostate, elucidating key molecular targets in this group of diseases. We have also shown that PARP inhibitors have antitumor activity against a significant proportion of these cancers, mainly in men whose cancers harbor DNA repair defects.
Farnesoid x receptor (fxr) and intestinal mucosa - Stefano FiorucciAttività scientifica
Bile acids activated receptors regulate the integrity of gastrointestinal mucosa focus on FXR.
Stefano Fiorucci,
MD Department of Surgical and Biomedical Sciences
University of Perugia
For The Japanese Society of Gastroenterology (JSGE) COI Disclosure
Alphabet Soup - Biomarker testing for colon and rectal cancer patients - KRAS...Fight Colorectal Cancer
Dr. Cathy Eng's presentation regarding biomarkers. Explaining why colon and rectal cancer patients should undergo testing for KRAS, NRAS and other tumor tests.
Translational Genomics and Prostate Cancer: Meet the NGS Experts Series Part 2QIAGEN
Advanced prostate cancer is highly heterogeneous but this inter-patient heterogeneity has until recently not been understood. We have through an international research effort dissected the molecular landscape of advanced castration resistant prostate, elucidating key molecular targets in this group of diseases. We have also shown that PARP inhibitors have antitumor activity against a significant proportion of these cancers, mainly in men whose cancers harbor DNA repair defects.
Farnesoid x receptor (fxr) and intestinal mucosa - Stefano FiorucciAttività scientifica
Bile acids activated receptors regulate the integrity of gastrointestinal mucosa focus on FXR.
Stefano Fiorucci,
MD Department of Surgical and Biomedical Sciences
University of Perugia
For The Japanese Society of Gastroenterology (JSGE) COI Disclosure
Never-smoker with Lung cancer in Southern California. Never-smokers with lung cancer have distinct genetic changes. Chao Family Comprehensive Cancer Center at UCI Irvine offers cutting edge clinical trials. Please call 1-714-456-8000
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchangeGul Muneer
Omalizumab is a widely used therapeutic anti-IgE antibody. Here we report the crystal structure of the omalizumab–Fab in complex with an IgE-Fc fragment. This structure reveals the mechanism of omalizumab-mediated inhibition of IgE interactions with both high- and low-affinity IgE receptors, and explains why omalizumab selectively binds free IgE. The structure of the complex also provides mechanistic insight into a class of disruptive IgE inhibitors that accelerate the dissociation of the high-affinity IgE receptor from IgE. We use this structural data to generate a mutant IgE-Fc fragment that is resistant to omalizumab binding. Treatment with this omalizumab-resistant IgE-Fc fragment, in combination with omalizumab, promotes the exchange of cell-bound full-length IgE with omalizumab-resistant IgE-Fc fragments on human basophils. This combination treatment also blocks basophil activation more efficiently than either agent alone, providing a novel approach to probe regulatory mechanisms underlying IgE hypersensitivity with implications for therapeutic interventions.
AGBT 2013: Home Brewed Personalized Genomics - The Quest for Meaningful Analy...Golden Helix Inc
Personalized genomics may be moving into a new era with whole-exome and whole-genome sequencing becoming affordable and available to consumers. 23andMe recently piloted a more affordable 80x exome to their existing customers. But it remains to be seen whether this wealth of raw genomic data can be analyzed to provide meaningful results for both healthy and symptomatic individuals.
By acquiring 23andMe exomes on his family, Gabe puts himself in the position of a bioinformatically inclined consumer, but non-clinician, to approach this question with his own analysis. His trio consists of a healthy father and son, and a mother with clinically-diagnosed idiopathic rheumatoid arthritis.
The following goals were set for the analysis: 1) How accurate are variant calls from direct-to-consumer NGS services? 2) How useful and durable is the list of risk variants provided by 23andMe? 3) Can a healthy individual's exome provide additional risk information over standard genotype-array-based risk prediction? and 4) Can the state of our current understanding of the complex genomic architecture of autoimmune diseases be enough to to find potential driver variants and genes to explain the diagnosis of a single case?
Here Gabe presents his findings of this analysis and discuss how individualized genomics might change in the world of affordable sequencing.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Newer Drug Delivery System_31-01-2024_Dr. Jeenal Mistry.pdfDr Jeenal Mistry
Advances in molecular pharmacology and an improved understanding of the mechanism of most diseases have created the need to specifically target the cells involved in the initiation and progression of diseases. This is especially true for most life-threatening diseases requiring therapeutic agents which have numerous side effects, thus requiring accurate tissue targeting to minimize systemic exposure. Recent drug delivery systems (DDS) are formulated using advanced technology to accelerate systemic drug delivery to the specific target site, maximizing therapeutic efficacy and minimizing off-target accumulation in the body. As a result, they play an important role in disease management and treatment. Recent DDS offer greater advantages when compared to conventional drug delivery systems due to their enhanced performance, automation, precision, and efficacy. They are made of nanomaterials or miniaturized devices with multifunctional components that are biocompatible, biodegradable, and have high viscoelasticity with an extended circulating half-life. This review, therefore, provides a comprehensive insight into the history and technological advancement of drug delivery systems. It updates the most recent drug delivery systems, their therapeutic applications, challenges associated with their use, and future directions for improved performance and use.
More Related Content
Similar to Dr Jeenal Mistry_Journal Club 2_12th March 2022.pdf
Never-smoker with Lung cancer in Southern California. Never-smokers with lung cancer have distinct genetic changes. Chao Family Comprehensive Cancer Center at UCI Irvine offers cutting edge clinical trials. Please call 1-714-456-8000
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchangeGul Muneer
Omalizumab is a widely used therapeutic anti-IgE antibody. Here we report the crystal structure of the omalizumab–Fab in complex with an IgE-Fc fragment. This structure reveals the mechanism of omalizumab-mediated inhibition of IgE interactions with both high- and low-affinity IgE receptors, and explains why omalizumab selectively binds free IgE. The structure of the complex also provides mechanistic insight into a class of disruptive IgE inhibitors that accelerate the dissociation of the high-affinity IgE receptor from IgE. We use this structural data to generate a mutant IgE-Fc fragment that is resistant to omalizumab binding. Treatment with this omalizumab-resistant IgE-Fc fragment, in combination with omalizumab, promotes the exchange of cell-bound full-length IgE with omalizumab-resistant IgE-Fc fragments on human basophils. This combination treatment also blocks basophil activation more efficiently than either agent alone, providing a novel approach to probe regulatory mechanisms underlying IgE hypersensitivity with implications for therapeutic interventions.
AGBT 2013: Home Brewed Personalized Genomics - The Quest for Meaningful Analy...Golden Helix Inc
Personalized genomics may be moving into a new era with whole-exome and whole-genome sequencing becoming affordable and available to consumers. 23andMe recently piloted a more affordable 80x exome to their existing customers. But it remains to be seen whether this wealth of raw genomic data can be analyzed to provide meaningful results for both healthy and symptomatic individuals.
By acquiring 23andMe exomes on his family, Gabe puts himself in the position of a bioinformatically inclined consumer, but non-clinician, to approach this question with his own analysis. His trio consists of a healthy father and son, and a mother with clinically-diagnosed idiopathic rheumatoid arthritis.
The following goals were set for the analysis: 1) How accurate are variant calls from direct-to-consumer NGS services? 2) How useful and durable is the list of risk variants provided by 23andMe? 3) Can a healthy individual's exome provide additional risk information over standard genotype-array-based risk prediction? and 4) Can the state of our current understanding of the complex genomic architecture of autoimmune diseases be enough to to find potential driver variants and genes to explain the diagnosis of a single case?
Here Gabe presents his findings of this analysis and discuss how individualized genomics might change in the world of affordable sequencing.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Newer Drug Delivery System_31-01-2024_Dr. Jeenal Mistry.pdfDr Jeenal Mistry
Advances in molecular pharmacology and an improved understanding of the mechanism of most diseases have created the need to specifically target the cells involved in the initiation and progression of diseases. This is especially true for most life-threatening diseases requiring therapeutic agents which have numerous side effects, thus requiring accurate tissue targeting to minimize systemic exposure. Recent drug delivery systems (DDS) are formulated using advanced technology to accelerate systemic drug delivery to the specific target site, maximizing therapeutic efficacy and minimizing off-target accumulation in the body. As a result, they play an important role in disease management and treatment. Recent DDS offer greater advantages when compared to conventional drug delivery systems due to their enhanced performance, automation, precision, and efficacy. They are made of nanomaterials or miniaturized devices with multifunctional components that are biocompatible, biodegradable, and have high viscoelasticity with an extended circulating half-life. This review, therefore, provides a comprehensive insight into the history and technological advancement of drug delivery systems. It updates the most recent drug delivery systems, their therapeutic applications, challenges associated with their use, and future directions for improved performance and use.
Drug Drug Interactions_27-01-2024_Dr. Jeenal Mistry.pdfDr Jeenal Mistry
In pharmaceutical sciences, drug interactions occur when a drug's mechanism of action is affected by the concomitant administration of substances such as foods, beverages, or other drugs. A popular example of drug-food interaction is the effect of grapefruit in the metabolism of drugs.
Interactions may occur by simultaneous targeting of receptors, directly or indirectly. For example, both Zolpidem and alcohol affect GABAA receptors, and their simultaneous consumption results in the overstimulation of the receptor, which can lead to loss of consciousness. When two drugs affect each other, it receives the name of a drug-drug interaction. The risk of a drug-drug interaction (DDI) increases with the number of drugs used.
A large share of elderly people regularly use five or more medications or supplements, with a significant risk of side-effects from drug-drug interactions.
Drug interactions can be of three kinds:
additive (the result is what you expect when you add together the effect of each drug taken independently),
synergistic (combining the drugs leads to a larger effect than expected), or
antagonistic (combining the drugs leads to a smaller effect than expected).
It may be difficult to distinguish between synergistic or additive interactions, as individual effects of drugs may vary.
Direct interactions between drugs are also possible and may occur when two drugs are mixed before intravenous injection. For example, mixing thiopentone and suxamethonium can lead to the precipitation of thiopentone.
Rational Use of Medicine_Evidence Based Medicine_Therapeutic Drug Monitoring_...Dr Jeenal Mistry
Rational use of Medicine: Irrational use of medicines is a major problem worldwide. WHO estimates that more than half of all medicines are prescribed, dispensed or sold inappropriately, and that half of all patients fail to take them correctly. The overuse, underuse or misuse of medicines results in wastage of scarce resources and widespread health hazards. Examples of irrational use of medicines include: use of too many medicines per patient ("poly-pharmacy"); inappropriate use of antimicrobials, often in inadequate dosage, for non-bacterial infections; over-use of injections when oral formulations would be more appropriate; failure to prescribe in accordance with clinical guidelines; inappropriate self-medication, often of prescription-only medicines; non-adherence to dosing regimes.
Evidence based medicine: Evidence-based medicine (EBM) is "the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients."The aim of EBM is to integrate the experience of the clinician, the values of the patient, and the best available scientific information to guide decision-making about clinical management. The term was originally used to describe an approach to teaching the practice of medicine and improving decisions by individual physicians about individual patients.
Therapeutic drug monitoring: Therapeutic drug monitoring (TDM) is a branch of clinical chemistry and clinical pharmacology that specializes in the measurement of medication levels in blood. Its main focus is on drugs with a narrow therapeutic range, i.e. drugs that can easily be under- or overdosed.
Topical Dosage Form practical session mainly for undergraduate students, those are learning competency based medicine with PH 2.1: Demonstrate an understanding of use of various dosage forms(Oral/Local/Parenteral ;Solid/Liquid)
Specific Learning Objectives:
The student should be able to:
•Enlist the common dosage forms used for oral route of administration
•Instruct the patient about the correct method of using an oral dosage form
•Describe the advantages and disadvantages of various dosage forms
ORAL ROUTE OF DRUG ADMINISTRATION_Dr. Jeenal Mistry.pdfDr Jeenal Mistry
Oral Dosage Form practical session mainly for undergraduate students, those are learning competency based with PH 2.1: Demonstrate an understanding of use of various dosage forms(Oral/Local/Parenteral ;Solid/Liquid)
Specific Learning Objectives:
The student should be able to:
•Enlist the common dosage forms used for oral route of administration
•Instruct the patient about the correct method of using an oral dosage form
•Describe the advantages and disadvantages of various dosage forms
Dr Jeenal Mistry_Recent Advances in DM_8th Sept 2022.pptxDr Jeenal Mistry
The pharmacotherapy of DM has evolved tremendously in the last
100 years since the successful extraction of insulin in 1921. The efficacy of multiple drugs has been established for microvascular and
macrovascular outcomes. Despite manufacturing successful insulinanalogues, newer analogues such as icodec and newer automated
insulin delivery pumps are in the pipeline to further improve glycaemic
control. CVOTs were initiated to establish the safety of antidiabetics;
however, apart from establishing efficacy as well, some drugs have
grown to the extent of establishing efficacy and safety in nondiabetic
patients as well. Current research must be directed towards new therapeutic options for TIDM and evaluating efficacy of antidiabetics for
diseases concomitantly associated with DM, such as cerebrovascular
diseases, neuropathies, retinopathies and cancers. Diabetes with
COVID-19 provides a therapeutic dilemma for establishing adequate
glycaemic control as well as managing complications. Numerous
hypotheses exist for the management of COVID-19 with diabetics,
which need to be evaluated. Various new drug delivery systems and
drugs with novel mechanisms of action, are in the pipeline for the
management of TIDM and TIIDM, with some of them demonstrating
adequate promise in clinical trials or other diseases.
Dr Jeenal Mistry_ Journal Club 3_6th August 2022.pptxDr Jeenal Mistry
CVN424 is a novel small molecule and first-in-class candidate therapeutic to selectively modulate GPR6, an orphan G-protein coupled receptor. Expression of GPR6 is largely confined to the subset of striatal projection neurons that give rise to the indirect(striatopallidal) pathway, important in the control of movement.
CVN424 improves motor function in preclinical animal models
of Parkinson’s disease. Here, we report results of a phase 1,
first-in-human study investigating the safety, tolerability, and
pharmacokinetics of CVN424 in healthy volunteers. The study
(NCT03657030) was randomized, double-blind, and placebo controlled. CVN424 was orally administered in ascending doses to successive cohorts as inpatients in a clinical research unit. Single
doses ranged from 1 mg to 225 mg, and repeated (7 day) daily
doses were 25, 75, or 150 mg. CVN424 peak plasma concentrations were reached within 2 h post-dose in the fasted state and increased with increasing dose. Dosing after a standardized high fat meal reduced and delayed the peak plasma concentration, but total plasma exposure was similar. Mean terminal half-life
ranged from 30 to 41 h. CVN424 was generally well tolerated:
no serious or severe adverse effects were observed, and there
were no clinically significant changes in vital signs or laboratory parameters. We conclude that CVN424, a nondopaminergic compound that modulates a novel therapeutic target, was
safe and well tolerated. A phase 2 study in patients with Parkinson’s disease is underway.
This is the first-in-human clinical study of a first-in-class candidate therapeutic. CVN424 modulates a novel drug target,
GPR6, which is selectively expressed in a pathway in the brain
that has been implicated in the motor dysfunction of patients
with Parkinson’s disease. This study paves the way for investigating this novel mechanism of action in patients with Parkinson’s disease.
The goal of reverse pharmacology is to utilize disease pathology in order to identify specific and targetable elements that novel compounds can be modeled from.
Now days due to various lifestyle people cannot able to sleep and having good sleep
There is difficulty in initiation, maintaining, & awakening during sleep.
I will try to help for understanding normal sleep, neurophysiology, sleep disorder & its Pharmacotherapy by this seminar session.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Dr Jeenal Mistry_Journal Club 2_12th March 2022.pdf
1. A Monoclonal Anti–Calcitonin Gene-Related
Peptide Antibody Decreases Stress-Induced
Colonic Hypersensitivity
Ehsan Noor-Mohammadi et al.
Department of Physiology
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma
Teva Pharmaceutical Industries, Ltd., Redwood City, California
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Year 2021, Volume 379, Issue 3 [page 270-279]
3. Calcitonin Gene Related Peptide
3
➢37-amino-acid member of the calcitonin family of peptides
➢Produced: peripheral and central neurons
➢Potent vasodilator
➢Function: Transmission of nociception
GI: Motility, secretion, and neuroprotection
11. Results
11
2. Anti-CGRP F(ab’)2 Inhibits Colonic Hypersensitivity Induced by WAS
without an Effect on Colonic Compliance
Two way ANOVA test followed by Bonferroni post test.
12. Results
12
3. Anti-CGRP F(ab’)2 Inhibits Thoracolumbar Spinal Cord Signaling Induced by
CRD in Rats Previously Exposed to WAS
0
1
2
3
4
5
Vehicle Isotype F(ab')2 Anti-CGRP
F(ab')2
T10-12
SHAM WAS
Average
Number
of
pERK-IR
cells/section
***
***
####
***P < 0.001 and ****P < 0.0001 compared with WAS 1 VEH; #### P < 0.0001 compared WAS 1 isotype F(ab’)2 control.
13. Results
13
3. Anti-CGRP F(ab’)2 Inhibits Thoracolumbar Spinal Cord Signaling Induced by
CRD in Rats Previously Exposed to WAS
Average
Number
of
pERK-IR
cells/section
0
1
2
3
4
5
Vehicle Isotype
F(ab')2
Anti-CGRP
F(ab')2
T13-L1
SHAM WAS
####
***P < 0.001 and ****P < 0.0001 compared with WAS 1 VEH; #### P < 0.0001 compared WAS 1 isotype F(ab’)2 control.
****
****
15. Results
15
4. Rodent Model of ELS: Behavioral Activation, Odor Preference, and
Weaning Weights
0
1
2
3
4
5
Odor Only Unpredictable
Odor Preference
Odor
Choices
0
10
20
30
40
50
Odor only Unpredictable
Weaning Weights
Weight
(gm)
16. Results
16
5. Anti-CGRP F(ab’)2 Inhibits Colonic Hypersensitivity in Adult Animals after
Neonatal Unpredictable ELS without an Effect on Colonic Compliance
17. Results
17
6. Anti-CGRP F(ab’)2 Inhibits Thoracolumbar Spinal Cord Signaling Induced
by CRD in Rats Previously Exposed to Neonatal Unpredictable ELS
0
2
4
6
8
Vehicle Isotype
F(ab')2
Anti-CGRP
F(ab')2
T10-12
Odor only Unpredictable
Average
Number
of
pERK-IR
cells/section
****
****
####
***P < 0.001 and ****P < 0.0001 compared with WAS 1 VEH; #### P < 0.0001 compared WAS 1 isotype F(ab’)2 control.
18. Results
18
6. Anti-CGRP F(ab’)2 Inhibits Thoracolumbar Spinal Cord Signaling Induced
by CRD in Rats Previously Exposed to Neonatal Unpredictable ELS
0
1
2
3
4
5
Vehicle Isotype
F(ab')2
Anti-CGRP
F(ab')2
T13-L1
Odor only Unpredictable
Average
Number
of
pERK-IR
cells/section
****
***
####
***P < 0.001 and ****P < 0.0001 compared with WAS 1 VEH; #### P < 0.0001 compared WAS 1 isotype F(ab’)2 control.
19. Discussion
19
To evaluate whether antibody mediated peripheral blockade
of CGRP prevented stress induced visceral pain in adulthood.
Repeated WAS
Unpredictable ELS
Peripheral CGRP
Colonic
hypersensitivity
Neuronal
activation
Dorsal horn of the
thoracolumbar spinal
cord
CGRP signalling
ELS-induced visceral
hypersensitivity
20. Conclusion
20
IBS : Multifaceted disorder Stress
early life
adulthood
F(ab’)2 fragment
antibody
Targeting CGRP inhibits
stress-induced colonic
hypersensitivity
Stimulus-evoked spinal
ERK1/2 phosphorylation
Regulation
of
persistent
visceral
pain
![A Monoclonal Anti–Calcitonin Gene-Related
Peptide Antibody Decreases Stress-Induced
Colonic Hypersensitivity
Ehsan Noor-Mohammadi et al.
Department of Physiology
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma
Teva Pharmaceutical Industries, Ltd., Redwood City, California
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Year 2021, Volume 379, Issue 3 [page 270-279]](https://image.slidesharecdn.com/drjeenalmistryjournalclub212thmarch2022-230315181930-4e3f8b7b/85/Dr-Jeenal-Mistry_Journal-Club-2_12th-March-2022-pdf-1-320.jpg)
